Nuformix plc (LON:NFX – Get Free Report) traded up 1.6% during trading on Monday . The company traded as high as GBX 0.07 ($0.00) and last traded at GBX 0.07 ($0.00). 24,372,961 shares were traded during mid-day trading, a decline of 54% from the average session volume of 52,647,891 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Performance
The firm has a 50-day simple moving average of GBX 0.06 and a two-hundred day simple moving average of GBX 0.10. The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The company has a market capitalization of £794,730.70, a price-to-earnings ratio of -1.63 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- What is a Stock Market Index and How Do You Use Them?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Calculate Options Profits
- What Does the Future Hold for Eli Lilly?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
